<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905591</url>
  </required_header>
  <id_info>
    <org_study_id>201712770</org_study_id>
    <secondary_id>3P30CA086862</secondary_id>
    <secondary_id>5U01CA140206</secondary_id>
    <secondary_id>1P01CA217797-01A1</secondary_id>
    <nct_id>NCT02905591</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC</brief_title>
  <acronym>XACT-LUNG</acronym>
  <official_title>A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph J. Cullen, MD, FACS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy&#xD;
      for non-small cell lung cancer. The standard therapy is radiation therapy combined with&#xD;
      carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose&#xD;
      ascorbate in addition to the standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For selected stages of non-small cell lung cancer (NSCLC), standard treatment involves&#xD;
      radiation therapy and chemotherapy. The chemotherapy regimen typically used is paclitaxel and&#xD;
      carboplatin. Both of these chemotherapeutic drugs are administered intravenously, using a&#xD;
      vein in the arm. Radiation is administered using a machine external to the body (usually a&#xD;
      linear accelerator). After combined therapy, NSCLC patients receive 2 extra cycles of&#xD;
      chemotherapy, called &quot;consolidation chemotherapy.&quot;&#xD;
&#xD;
      This study adds 75 grams of ascorbate (vitamin C, sometimes called pharmacological ascorbate&#xD;
      because the dose is so high) at specific timepoints in the therapy. The ascorbate is&#xD;
      administered intravenously - through a vein in your arm.&#xD;
&#xD;
      Participants will:&#xD;
&#xD;
        -  receive 75 grams of intravenous ascorbate 3 times per calendar week while they are&#xD;
           receiving radiation therapy. The IV will be running while the radiation therapy is&#xD;
           administered.&#xD;
&#xD;
        -  undergo imaging which is standard for their cancer and therapy. This can include CT&#xD;
           scans, PET scans, and X-rays.&#xD;
&#xD;
        -  provide blood samples to determine the biological effects, if any, the ascorbate has on&#xD;
           the body during therapy&#xD;
&#xD;
      This active therapy portion lasts for about 10 to 12 weeks. After that is done, participants&#xD;
      go back to standard follow-up for their cancer and any additional therapy their doctors&#xD;
      believe they need.&#xD;
&#xD;
      However, it is very important the investigators remain in contact with participants; they&#xD;
      will have life-long follow-up for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression rate at completion of radiation and chemotherapy</measure>
    <time_frame>3 to 4 weeks after last radiation treatment</time_frame>
    <description>Tumor measurement from CT scan, using the RECIST criteria to define progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every six months for up to 20 years post-treatment</time_frame>
    <description>From radiation day 1 to documented disease progression as described by RECIST criteria. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Every six months for up to 20 years post-treatment</time_frame>
    <description>Time, measured in days, it takes for disease to progress, where disease progression is defined by the RECIST criteria (v1.1). Timeframe is from radiation day 1 to date of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Every three months for up to 20 years post-treatment</time_frame>
    <description>Time, measured in months, from start of radiation to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event frequency and categorization</measure>
    <time_frame>Weekly for the first 7 weeks, then monthly for 3 months, then every 6 months through 2 years post-treatment</time_frame>
    <description>Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (CTCAE, v 4) as follows:&#xD;
Through radiation, weekly assessment of adverse events&#xD;
Consolidation chemotherapy, assessment day 1 of each cycle&#xD;
Post-treatment, every 6 months through 2 years post-therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>ChemoRT + Ascorbate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days</description>
    <arm_group_label>ChemoRT + Ascorbate</arm_group_label>
    <other_name>external beam radiation therapy (EBRT)</other_name>
    <other_name>intensity modulated radiation therapy (IMRT)</other_name>
    <other_name>Volumetric Arc Therapy (VMAT)</other_name>
    <other_name>XRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered&#xD;
the dose is 45 mg/m2 (standard dose)&#xD;
Administered weekly&#xD;
6 to 7 weeks of therapy, depending on when radiation starts&#xD;
Standardized dose reductions are used</description>
    <arm_group_label>ChemoRT + Ascorbate</arm_group_label>
    <other_name>Nov-Onxol</other_name>
    <other_name>Onxol</other_name>
    <other_name>Paclitaxel Novaplus</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.&#xD;
Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)&#xD;
Administered weekly&#xD;
6 to 7 weeks of therapy, depending on when radiation starts&#xD;
Standard dose reductions are used</description>
    <arm_group_label>ChemoRT + Ascorbate</arm_group_label>
    <other_name>NovaPlus CARBOplatin</other_name>
    <other_name>Amerinet Choice Carboplatin</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin NovaPlus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Administered intravenously&#xD;
75 grams per infusion; each infusion is about 2 hours&#xD;
3 infusion per calendar week&#xD;
The infusion is actively running for at least 20 minutes when radiation begins&#xD;
May be given while chemotherapy is delayed due to low counts&#xD;
Dose reductions are not used&#xD;
Given for 6 to 7 weeks, depending on when radiation starts</description>
    <arm_group_label>ChemoRT + Ascorbate</arm_group_label>
    <other_name>Ascorbate</other_name>
    <other_name>Vitamin C</other_name>
    <other_name>Pharmacological ascorbate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Note: patients who have a small pleural effusion that is too small to safety tap and is not&#xD;
        visible on a chest x-ray are still eligible&#xD;
&#xD;
          -  Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) of&#xD;
             non-small cell lung cancer.&#xD;
&#xD;
          -  Recommended to receive carboplatin &amp; paclitaxel with radiation therapy as a treatment&#xD;
&#xD;
          -  Tumor or metastatic disease must measure at least 1 cm using a CT scan (CAT scan)&#xD;
&#xD;
          -  Physician determined the patient is healthy enough for chemotherapy and radiation&#xD;
             therapy&#xD;
&#xD;
          -  At least part of the lung cancer must be viewable and measurable by CT or MRI&#xD;
&#xD;
          -  A platelet count of at least 100,000 cells per mililiter&#xD;
&#xD;
          -  A creatinine level of less than 1 1/2 times the upper limit of normal for the local&#xD;
             lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)&#xD;
&#xD;
          -  Not pregnant, and commit to using birth control during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exudative pleural effusion&#xD;
&#xD;
          -  Recurrent non-small cell lung cancer&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Patients actively receiving insulin or patients whose doctors have recommended current&#xD;
             insulin use&#xD;
&#xD;
          -  Patients requiring daily finger-stick blood glucose measurements&#xD;
&#xD;
          -  Patients who are on the following drugs and cannot have a substitution or who decline&#xD;
             the substitution:&#xD;
&#xD;
               -  warfarin&#xD;
&#xD;
               -  flecainide&#xD;
&#xD;
               -  methadone&#xD;
&#xD;
               -  amphetamines&#xD;
&#xD;
               -  quinidine&#xD;
&#xD;
               -  chlorpropamide&#xD;
&#xD;
          -  Prior radiation therapy that would result in a field overlap&#xD;
&#xD;
          -  Enrolled in another therapeutic clinical trial&#xD;
&#xD;
          -  Uncontrolled, intercurrent illness&#xD;
&#xD;
          -  Lactating women&#xD;
&#xD;
          -  HIV positive individuals undergoing therapy due to known drug:drug interaction between&#xD;
             antiretroviral drugs and high-dose ascorbate therapy&#xD;
&#xD;
        If all the above are met, the potential participant will receive a 15 gram challenge dose&#xD;
        of ascorbate via intravenous infusion. This is the final screening procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J Cullen, MD, FACS</last_name>
    <role>Study Director</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan G Allen, MD, PhD</last_name>
    <phone>319-353-8836</phone>
    <email>bryan-allen@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muhammad Furqan, MD</last_name>
    <phone>319-356-1527</phone>
    <email>muhammad-furqan@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Cener</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt, RN, BSN, OCN</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Brown, RN, BAN, OCN</last_name>
      <phone>319-384-7912</phone>
      <email>heather-brown@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bryan G Allen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammad Furqan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(â‹…-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.</citation>
    <PMID>28366679</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Bryan Allen</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>pharmacological ascorbate</keyword>
  <keyword>ascorbic acid</keyword>
  <keyword>radiation</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>carboplatin</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be shared upon request in compliance with the IRB application and protocol.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Upon request.</ipd_time_frame>
    <ipd_access_criteria>Contact the investigator or sub-investigator to initiate a request. A contract may be required between institutions. Data will be shared only from those participants who consented to sharing.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

